BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16390748)

  • 1. The effect of 6 months of androgen deprivation therapy on muscle and fat mass in older men with localized prostate cancer.
    Boxer RS; Kenny AM; Dowsett R; Taxel P
    Aging Male; 2005; 8(3-4):207-12. PubMed ID: 16390748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical relevance of adiposity when assessing muscle health in men treated with androgen deprivation for prostate cancer.
    Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
    J Cachexia Sarcopenia Muscle; 2019 Oct; 10(5):1036-1044. PubMed ID: 31067013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time on androgen deprivation therapy and adaptations to exercise: secondary analysis from a 12-month randomized controlled trial in men with prostate cancer.
    Taaffe DR; Buffart LM; Newton RU; Spry N; Denham J; Joseph D; Lamb D; Chambers SK; Galvão DA
    BJU Int; 2018 Feb; 121(2):194-202. PubMed ID: 28872752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between circulating FSH levels and body composition and bone health in patients with prostate cancer who undergo androgen deprivation therapy: The BLADE study.
    Bergamini M; Dalla Volta A; Palumbo C; Zamboni S; Triggiani L; Zamparini M; Laganà M; Rinaudo L; Di Meo N; Caramella I; Bresciani R; Valcamonico F; Borghetti P; Guerini A; Farina D; Antonelli A; Simeone C; Mazziotti G; Berruti A
    Elife; 2024 Apr; 13():. PubMed ID: 38656229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does Use of Androgen Deprivation Therapy (ADT) in Men with Prostate Cancer Increase the Risk of Sarcopenia?
    Owen PJ; Daly RM; Dalla Via J; Mundell NL; Livingston PM; Rantalainen T; Fraser SF
    Calcif Tissue Int; 2019 Oct; 105(4):403-411. PubMed ID: 31317232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2004 Apr; 63(4):742-5. PubMed ID: 15072892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
    Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
    J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.
    Levy ME; Perera S; van Londen GJ; Nelson JB; Clay CA; Greenspan SL
    Urology; 2008 Apr; 71(4):735-9. PubMed ID: 18279933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate versus delayed exercise in men initiating androgen deprivation: effects on bone density and soft tissue composition.
    Taaffe DR; Galvão DA; Spry N; Joseph D; Chambers SK; Gardiner RA; Hayne D; Cormie P; Shum DHK; Newton RU
    BJU Int; 2019 Feb; 123(2):261-269. PubMed ID: 30239116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for reduced neuromuscular function in men with a history of androgen deprivation therapy for prostate cancer.
    Girard D; Marino FE; Cannon J
    Clin Physiol Funct Imaging; 2014 May; 34(3):209-17. PubMed ID: 24119067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial.
    Dawson JK; Dorff TB; Todd Schroeder E; Lane CJ; Gross ME; Dieli-Conwright CM
    BMC Cancer; 2018 Apr; 18(1):368. PubMed ID: 29614993
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationships between insulin resistance and frailty with body composition and testosterone in men undergoing androgen deprivation therapy for prostate cancer.
    Cheung AS; Hoermann R; Dupuis P; Joon DL; Zajac JD; Grossmann M
    Eur J Endocrinol; 2016 Sep; 175(3):229-37. PubMed ID: 27340081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.
    Berruti A; Dogliotti L; Terrone C; Cerutti S; Isaia G; Tarabuzzi R; Reimondo G; Mari M; Ardissone P; De Luca S; Fasolis G; Fontana D; Rossetti SR; Angeli A;
    J Urol; 2002 Jun; 167(6):2361-7; discussion 2367. PubMed ID: 11992038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term effects of androgen deprivation therapy in prostate cancer patients.
    Basaria S; Lieb J; Tang AM; DeWeese T; Carducci M; Eisenberger M; Dobs AS
    Clin Endocrinol (Oxf); 2002 Jun; 56(6):779-86. PubMed ID: 12072048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer.
    Galvão DA; Spry NA; Taaffe DR; Newton RU; Stanley J; Shannon T; Rowling C; Prince R
    BJU Int; 2008 Jul; 102(1):44-7. PubMed ID: 18336606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Football training improves lean body mass in men with prostate cancer undergoing androgen deprivation therapy.
    Uth J; Hornstrup T; Schmidt JF; Christensen JF; Frandsen C; Christensen KB; Helge EW; Brasso K; Rørth M; Midtgaard J; Krustrup P
    Scand J Med Sci Sports; 2014 Aug; 24 Suppl 1():105-12. PubMed ID: 24944134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body composition, fatigue and exercise in patients with prostate cancer undergoing androgen-deprivation therapy.
    Newton RU; Jeffery E; Galvão DA; Peddle-McIntyre CJ; Spry N; Joseph D; Denham JW; Taaffe DR
    BJU Int; 2018 Dec; 122(6):986-993. PubMed ID: 29750398
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Androgen Deprivation Therapy on Extraocular Muscles, Retrobulbar Orbital Fat, and the Optic Nerve in Patients with Prostate Cancer.
    Sonmez HK; Sonmez G; Dogan S; Horozoglu F; Demirtas A; Evereklioglu C
    Ophthalmic Res; 2023; 66(1):272-280. PubMed ID: 36228576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in body composition during androgen deprivation therapy for prostate cancer.
    Smith MR; Finkelstein JS; McGovern FJ; Zietman AL; Fallon MA; Schoenfeld DA; Kantoff PW
    J Clin Endocrinol Metab; 2002 Feb; 87(2):599-603. PubMed ID: 11836291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute versus chronic exposure to androgen suppression for prostate cancer: impact on the exercise response.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    J Urol; 2011 Oct; 186(4):1291-7. PubMed ID: 21849187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.